Invivyd, Inc. (IVVD)
0.9634
-0.06
(-5.55%)
USD |
NASDAQ |
Sep 22, 13:27
Invivyd Enterprise Value : 148.96M for Sept. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 21, 2026 | 148.96M |
| September 18, 2026 | 70.94M |
| September 17, 2026 | 68.26M |
| September 16, 2026 | 85.68M |
| September 15, 2026 | 92.96M |
| September 14, 2026 | 111.17M |
| September 11, 2026 | 79.84M |
| September 10, 2026 | 77.01M |
| September 09, 2026 | 83.32M |
| September 08, 2026 | 91.72M |
| September 04, 2026 | 91.78M |
| September 03, 2026 | 94.43M |
| September 02, 2026 | 85.29M |
| September 01, 2026 | 107.67M |
| August 31, 2026 | 129.77M |
| August 28, 2026 | 132.60M |
| August 27, 2026 | 113.62M |
| August 26, 2026 | 114.09M |
| August 25, 2026 | 125.00M |
| August 24, 2026 | 126.12M |
| August 21, 2026 | 142.03M |
| August 20, 2026 | 128.56M |
| August 19, 2026 | 131.13M |
| August 18, 2026 | 104.19M |
| August 17, 2026 | 66.58M |
| Date | Value |
|---|---|
| August 14, 2026 | 60.80M |
| August 13, 2026 | 50.42M |
| August 12, 2026 | 64.07M |
| August 11, 2026 | 50.96M |
| August 10, 2026 | 46.71M |
| August 07, 2026 | 66.43M |
| August 06, 2026 | 42.55M |
| August 05, 2026 | 26.46M |
| August 04, 2026 | 17.26M |
| August 03, 2026 | 10.90M |
| July 31, 2026 | 6.005M |
| July 30, 2026 | 19.74M |
| July 29, 2026 | 8.363M |
| July 28, 2026 | 23.19M |
| July 27, 2026 | 28.08M |
| July 24, 2026 | 28.52M |
| July 23, 2026 | 27.88M |
| July 22, 2026 | 31.09M |
| July 21, 2026 | 49.25M |
| July 20, 2026 | 50.31M |
| July 17, 2026 | 67.17M |
| July 16, 2026 | 80.55M |
| July 15, 2026 | 89.13M |
| July 14, 2026 | 84.35M |
| July 13, 2026 | 80.43M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 619.65M |
| Amgen, Inc. | 255.86B |
| Anika Therapeutics, Inc. | 263.87M |
| BioCryst Pharmaceuticals, Inc. | 2.720B |
| Imunon, Inc. | 7.653M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -44.39M |
| Revenue (Quarterly) | 14.28M |
| Total Expenses (Quarterly) | 58.68M |
| EPS Diluted (Quarterly) | -0.1385 |
| Gross Profit Margin (Quarterly) | 86.62% |
| Profit Margin (Quarterly) | -310.8% |
| Earnings Yield | -38.72% |
| Normalized Earnings Yield | -38.72 |